Alligator Bioscience, BioInvent deal

BioInvent sold back all rights to preclinical cancer compound ADC-1013 to former partner Alligator for an undisclosed sum. BioInvent has successfully manufactured the antibody-based CD40 receptor activator immunotherapy and will fulfill the remaining activities required to supply drug product to the Phase I/II trial to treat solid tumors expected to begin by year end. The companies declined to disclose financial terms. ...